Alaunos Therapeutics IncTCRT
Price$0.89

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $3K-70.0% YoYTTM through 30 Jun 2026
Net Income -$4MTTM through 30 Jun 2026
Free Cash Flow -$2.8MTTM through 30 Jun 2026

Margins

Current
Operating Margin-84,500.0%
Net Margin-133,666.7%

Returns

-194.0%ROE
-140.6%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.65x
Net Debt-$1.4Mnet cash position
Cash & Equivalents$124K

Quality Metrics

Altman Z-Score-862.43
Piotroski F-Score1 / 9
FCF Margin-94,166.7%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'18'20'21'22'23'24'25
FY2025: $5K
Diluted EPS-$1.75TTM
'19'20'21'22'23'24'25
FY2025: $-2.14

Dividend

No dividend

Capital Allocation

Capex Intensity3,266.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.